TREMFYA
TREMFYA (Guselkumab) is an FDA-approved monoclonal antibody therapy indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult patients. Each 1×1 mL prefilled syringe contains Guselkumab, designed for subcutaneous administration under professional supervision.
Guselkumab works by selectively inhibiting interleukin-23 (IL-23), a key cytokine involved in the inflammatory pathways of psoriasis and psoriatic arthritis. By blocking IL-23, TREMFYA helps reduce plaque formation, alleviate joint inflammation, and improve overall skin and joint outcomes, providing patients with a targeted and effective treatment option.
InfusionMed USA, based in Carrollton, Texas, supplies TREMFYA and other specialty dermatology and rheumatology therapies to clinics, hospitals, and specialty infusion centers throughout Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain compliance, proper handling, and timely delivery for licensed healthcare providers.
For professional use only.
Download Form